Skip to main content

Day: June 3, 2020

ERYTECH nimmt an Kamingespräch auf Jefferies Virtual Healthcare Conference teil

LYON, Frankreich und CAMBRIDGE, Massachusetts, June 03, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq und Euronext: ERYP), ein klinisch forschendes biopharmazeutisches Unternehmen, das innovative Therapien entwickelt, indem es Wirkstoffe in roten Blutkörperchen einkapselt, hat heute bekannt gegeben, dass Gil Beyen, CEO, am 4. Juni 2020 um 08:30 Uhr (Eastern Time) an einem Kamingespräch auf der Jefferies Virtual Healthcare Conference teilnehmen wird.Präsentationsdetails:Veranstaltung: Jefferies Virtual Healthcare Conference – FragerundeDatum: Donnerstag, 4. Juni 2020Uhrzeit: 08:30 Uhr bis 08:55 Uhr (Eastern Time)Über ERYTECH und EryaspaseERYTECH ist ein biopharmazeutisches Unternehmen, das klinische Studien zu verschiedenen Arzneimitteln durchführt und innovative Erythrozyten-basierte Therapeutika für schwere Krebserkrankungen und...

Continue reading

ERYTECH parteciperà a una Fireside Chat durante la Jefferies Virtual Healthcare Conference

LIONE, Francia e CAMBRIDGE, Mass., June 03, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), un’azienda biofarmaceutica in fase clinica che sviluppa terapie innovative incapsulando sostanze farmacologiche terapeutiche all’interno dei globuli rossi, ha annunciato in data odierna che Gil BEYEN, Amministratore delegato, parteciperà a una Fireside Chat (una conversazione informale) durante la Jefferies Virtual Healthcare Conference il 4 giugno 2020 alle ore 8:30 ET (14:30 CET).Dettagli presentazione:Evento: Jefferies Virtual Healthcare Conference – sessione di Q&AData: giovedì 4 giugno 2020Orario: dalle 08:30 alle 08:55 ET (dalle 14:30 alle 14:55 CET)Informazioni su ERYTECH ed eryaspaseERYTECH è un’azienda biofarmaceutica di fase clinica che sviluppa terapie innovative basate sui globuli rossi per il...

Continue reading

Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

WOBURN, Mass., June 03, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing a series of oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced financial results for the fiscal fourth quarter and year ended March 31, 2020 and provided a business update.“I am very pleased with our continued progress developing our pipeline of oncolytic immuno-gene therapies. Today we released additional data with RP1 in our lead indications of cutaneous squamous cell carcinoma (CSCC) and anti-PD1 refractory cutaneous melanoma that we believe point to a high probability of success in our registration-directed clinical trial in CSCC and our potentially registrational cohort of patients currently being enrolled with anti-PD1 refractory melanoma.  We also today announced plans to...

Continue reading

CURE Pharmaceutical [OTCQB:CURR] Expands to Mexico in Collaboration with Factoria Bogar Subsidiary

OXNARD, Calif., June 03, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico. PMI will have access to CURE’s innovative drug delivery platform, CUREform™ for its drug formulation, as well as become its distribution partner in Mexico for CURE’s wellness products, such as its vitamin D supplement, sleep and CBD combination products.“This collaboration enables us to reach new markets with our suite of wellness products as well as prompt innovation with new drug formulations and conduct valuable patient studies on drug efficacy,” said Rob Davidson, CEO of CURE. “This is a valuable partnership from both a revenue perspective as well as an opportunity to expand product offerings and...

Continue reading

BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma

BEIJING, China and CAMBRIDGE, Mass., June 03, 2020 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its BTK inhibitor BRUKINSA™ (zanubrutinib) has received approval from the China National Medical Products Administration (NMPA) in two indications – the treatment of adult patients with chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) who have received at least one prior therapy, and the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the...

Continue reading

Kingsoft Cloud Announces Unaudited First Quarter 2020 Financial Results

BEIJING, June 03, 2020 (GLOBE NEWSWIRE) — Kingsoft Cloud Holdings Limited (“Kingsoft Cloud” or the “Company”) (NASDAQ: KC), a leading independent cloud service provider in China, today announced its unaudited financial results for the first quarter ended March 31, 2020.First Quarter 2020 Financial HighlightsTotal revenues were RMB1,391.0 million (US$1196.4 million) in the first quarter of 2020, representing an increase of 64.5 % year-over-year.Gross profit was RMB70.8 million (US$10.0 million) or 5.1% gross margin in the first quarter of 2020, compared with gross loss of RMB45.1million or -5.3% gross margin in the first quarter of 2019.Non-GAAP gross profit2, was RMB74.2 million (US$10.5 million) or 5.3% Non-GAAP gross margin in the first quarter of 2020, compared with Non-GAAP gross loss of RMB44.6 million...

Continue reading

Hoylu AB: Publishes its Annual Report for 2019 (correction: in the previous PR an incorrect reference was made to MAR, it is now deleted)

Hoylu AB (publ) announced today that the Annual Report for 2019 is available at Hoylu’s web site:https://www.hoylu.com/investor-relations/financial-reports/For more information, please contact:Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.comKarl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.comAbout HoyluHoylu’s mission is to make remote work and information sharing easy. Through our customizable Connected Workspaces™ we deliver software solutions for companies, organizations and individuals across virtually all industries that enable all teams, big and small to work efficiently and securely in an intuitive and easy workflow.For more information: www.hoylu.com.

Continue reading

Hoylu AB: Publicerar årsredovisning för 2019 (rättelse: i tidigare PM gjordes en felaktig hänvisning till MAR, den är nu borttagen)

Hoylu AB (publ) meddelar idag att årsredovisningen för räkenskapsåret 2019 finns tillgänglig på bolagets hemsida:https://www.hoylu.com/investor-relations/financial-reports/För ytterligare information, vänligen kontakta:Stein Revelsby, VD på Hoylu + 1 213 440 2499 e-post: sr@hoylu.comKarl Wiersholm, CFO på Hoylu + 1 425 829 2316 e-post: kw@hoylu.comOm HoyluHoylus uppdrag är att göra distansarbete och informationsutbyte enkelt. Genom vår anpassningsbara Connected Workspaces™ levererar vi programvarulösningar till företag, organisationer och individer i praktiskt taget alla branscher som gör det möjligt för alla team, stora som små att arbeta effektivt och säkert i ett intuitivt och enkelt arbetsflöde. För mer information: www.hoylu.comKortnamn: HoyluMarknadsplats: Nasdaq First North Growth MarketCertified Adviser: Mangold Fondkommission...

Continue reading

Resonant Inc. to Participate in the Stifel 2020 Virtual Cross Sector Insight Conference

GOLETA, Calif., June 03, 2020 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, is scheduled to participate in a fireside chat at the Stifel 2020 Virtual Cross Sector Insight Conference on Wednesday, June 10, 2020, at 11:20 a.m. ET.Management plans to provide a business update and industry overview focusing on the company’s strategy within its served mobile market and emerging target non-mobile market, in particular giving an update on Resonant’s efforts to bring its industry-leading XBAR® technology to the non-mobile RF filter marketplace. Filters based on XBAR technology address the wide bandwidth, high frequency requirements of new 5G and WiFi devices in both mobile and non-mobile applications.Resonant...

Continue reading

Pain Management Devices Market to Witness 9.1% CAGR; Boston Scientific’s ‘Spectra WaveWriter’ Launch to Enable Growth, says Fortune Business Insights

Pune, June 03, 2020 (GLOBE NEWSWIRE) — The global pain management devices market will benefit from increasing regulatory approvals for neuromodulation devices in recent years. According to a report published by Fortune Business Insights, titled “Pain Management Devices: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 3,922.9 Mn in 2018. Fortune Business Insights states that the market will reach US$ 8,046.3 Mn by 2026, exhibiting a CAGR of 9.4%.Pain management devices aid in reducing chronic pain and other undesirable conditions. Pain management can be used as an alternative to surgery to improve the result of your medication. This allows a non-invasive platform for surgical procedures, which in turn will lead to an increase in the global pain management devices market value. Recent technological...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.